In an effort to limit unnecessary testing and increase diagnostic yield, current major guideline recommendations recommend a risk-based strategy with deferred testing in low-risk patients, catheterization in high risk patients, and selective noninvasive testing for those at intermediate risk. To date, no randomized trial has explored the clinical efficacy and safety of any such strategy.

In this interview, Pamela S Douglas MD, MACC and Anthony N. DeMaria MD, MACC discuss Real World Implications of 2021 AHA/ACC Chest Pain Guidelines: Modeling of Deferred Testing Recommendations in the PROMISE Trial.

Related References:

• Nanna MG, Vemulapalli S, Fordyce CB, et al. The prospective randomized trial of the optimal evaluation of cardiac symptoms and revascularization: Rationale and design of the PRECISE trial. Am Heart J 2022; 245: 136-48

Clinical Topics: Acute Coronary Syndromes, Heart Failure and Cardiomyopathies, Noninvasive Imaging

Keywords: ACCELLite, Chest Pain

< Back to Listings